Atomization connecting piece and mouth-nose inhalation exposure system

Abstract

A nebulization connector and an oral-nasal inhalation exposure system. The utility model relates to an atomization connecting piece, which is used for inhalation preparation animal experiments, is connected with an atomizer used for atomizing raw medicine and an exposure cabin communicated with a fixer for accommodating experimental animals, and comprises a connecting base, a first communicating pipe, a second communicating pipe and an adjusting piece, and one side of the connecting base and the exposure cavity are sealed to form an exposure cavity; the other side of the first communicating pipe is fixedly communicated with the second communicating pipe and the plurality of first communicating pipes; the first communicating pipe is fixedly communicated with the atomizer; the multiple adjusting pieces are arranged on the multiple first communicating pipes in a communicating mode and used for selectively adjusting the pipeline circulation state of the first communicating pipes; the second communicating pipe and the first communicating pipe do not interfere with each other, the second communicating pipe is connected with external equipment, and the second communicating pipe is used for reducing the pressure in the exposure cavity through the external equipment and / or diluting the concentration of the raw medicine in the exposure cavity through the external equipment.

Description

Technical Field

[0001] The utility model relates to an atomizing connector or an oral-nasal inhalation exposure system, in particular to an atomizing connector and an oral-nasal inhalation exposure system. Background Art

[0002] With the increasing efforts in drug research and development at home and abroad, atomized inhalation therapy is being explored and excavated more and more. Inhalation preparations are no longer limited to the treatment of traditional respiratory diseases such as asthma and chronic obstructive pulmonary disease. They can also be used to treat cardiovascular diseases (coronary heart disease, angina pectoris, etc.), cerebrovascular diseases (stroke, cerebral infarction, migraine, etc.), endocrine diseases (diabetes, etc.), analgesia, nervous system diseases, etc. Inhalation administration is more attractive as another route of administration besides oral and intravenous administration. Inhalation preparations are portable and have good patient compliance. At the same time, they can not only use their physical targeting and local medication to treat lung diseases; they can also use the large lung absorption surface area and rich vascular network for systemic administration of biomacromolecules and poorly soluble drugs. Compared with intravenous injection, inhalation preparations have less mechanical damage, convenient operation, and better patient compliance; compared with oral preparations, inhalation preparations have higher bioavailability and can act directly on the lungs. Lung inhalation preparations are the first choice for the treatment of respiratory system diseases. In recent years, due to the influence of the environment, the incidence of respiratory system diseases has been increasing. Pulmonary inhalation preparations have a fast onset of action, high bioavailability, and few side effects. They are ideal dosage forms for the treatment of respiratory diseases. Inhalation administration has also received more and more attention and recognition, and has great clinical application value. Considering the onset time and efficacy, inhalation preparations have always been the mainstream treatment for respiratory diseases in the European and American markets.

[0003] Animal experiments are a basic requirement for drug research because they can best reflect the dynamic interactions between the various cells, tissues, and organs that make up the human body. Before submitting an IND for an innovative drug, it is necessary to fully conduct tissue distribution tests, acute toxicity tests, repeated dose toxicity tests, irritation tests, allergy tests, safety pharmacology, pharmacokinetics, pharmacodynamics and other tests on animals. The oral and nasal inhalation exposure system is one of the most commonly used non-clinical research instruments, and rats are commonly used animals for evaluating the toxicity of biological drug test products, and there is a large amount of historical data.

[0004] In the prior art, the oral and nasal inhalation system mainly includes a nebulizer for atomizing the original drug, an exposure chamber for connecting to the nebulizer, and a plurality of holders for accommodating animals connected to the exposure chamber. In this case, the dosage is highly dependent on the original drug concentration and the atomization efficiency of the nebulizer.

[0005] However, for new inhalation preparations, especially innovative biological drugs, the preparation process is complex, and the drug dosage prepared in the research and development stage is generally in the ug and mg level, and the original drug concentration is very low; and even if the existing oral and nasal inhalation exposure system nebulizer generator is set to the maximum aerosol generation efficiency, a single nebulizer cannot meet the target aerosol dosage required for non-clinical efficacy, pharmacokinetic and safety evaluation studies. Therefore, it is often necessary to concentrate the existing original drug to increase the aerosol concentration to meet the target dosage of experimental animals, reducing experimental efficiency.

[0006] In addition, since the technical drugs of each component are mixed before atomization and then atomized, the dosage cannot be estimated, which often results in waste of the mixed technical drugs, resulting in a large amount of technical drug waste, which is particularly unacceptable in the context of high technical drug preparation costs.

[0007] Therefore, the prior art needs to be improved urgently. Utility Model Content

[0008] In view of the shortcomings of the prior art, the purpose of the present utility model is to provide an atomization connector or an oral and nasal inhalation exposure system for at least improving the experimental efficiency in oral and nasal inhalation animal experiments.

[0009] In order to achieve the above-mentioned purpose, the first aspect of the present invention adopts the following technical solutions:

[0010] A nebulizer connector connects a nebulizer for nebulizing a raw drug and an exposure chamber connected to a fixture for accommodating experimental animals, comprising a connecting base, a first connecting pipe, a second connecting pipe and an adjusting member, wherein one side of the connecting base is sealed with the exposure chamber to form an exposure chamber, and the other side is fixedly connected with the second connecting pipe and a plurality of the first connecting pipes; the first connecting pipe is fixedly connected with the nebulizer; a plurality of adjusting members are respectively connected and arranged on a plurality of the first connecting pipes, and are used for selectively adjusting the pipeline flow state of the first connecting pipes; the second connecting pipe does not interfere with the first connecting pipe, and the second connecting pipe is connected to an external device, wherein the second connecting pipe is used to reduce the pressure in the exposure chamber through the external device, and / or is used to dilute the raw drug concentration in the exposure chamber through the external device.

[0011] As an embodiment of the utility model, the first connecting pipe includes a root and a tip that are fixedly connected, one end of the root is fixedly connected to the connecting base, and the other end is fixedly connected to the tip, and an end of the tip away from the root is fixedly connected to the atomizer, wherein the root is arranged along the axial direction of the connecting base; the tip is inclined along the radial direction of the connecting base, and an end of the tip connected to the atomizer is arranged on the side away from the axis of the connecting base relative to an end of the tip connected to the root.

[0012] As an implementation manner of the present utility model, a plurality of the first connecting tubes are evenly arranged in the circumferential direction of the connecting base, and the second connecting tube is arranged between the plurality of the first connecting tubes.

[0013] As an embodiment of the present utility model, the regulating member is a valve connected to the first connecting pipe; or the regulating member is a plugging member detachably sealed and connected to the tip, the plugging member matches the end of the tip away from the root, and the tip is detachably fixedly connected to the atomizer.

[0014] As an implementation mode of the utility model, the valve connection is arranged at a side of the root of the first connecting pipe close to the connecting base; the valve is a solenoid valve, or a manual shut-off valve.

[0015] As an embodiment of the present utility model, the second connecting pipe is also used to clean the exposure cavity through the external device.

[0016] As an embodiment of the utility model, it also includes a ring, and a plurality of the rings are respectively fixed on one end of the plurality of first connecting tubes close to the atomizer, or a plurality of the rings are respectively movably sleeved on one end of the plurality of first connecting tubes close to the atomizer and are sealedly connected to the first connecting tube; a plurality of the rings are respectively detachably and sealably connected to a plurality of the atomizers.

[0017] The second aspect of the utility model provides an oral and nasal inhalation exposure system, comprising a nebulizer for atomizing the original drug, a fixture for accommodating experimental animals, an exposure chamber and the nebulizer connector described in the first aspect of the utility model, wherein the nebulizer connector is used to connect the exposure chamber and the multiple nebulizers, and the nebulizer connector is sealed with the exposure chamber to form an exposure chamber; the exposure chamber is connected to the multiple fixtures, and the exposure chamber is used to mix the original drugs in the multiple nebulizers and then deliver them to the multiple fixtures.

[0018] As an implementation mode of the utility model, a drug adding port for adding the original drug is arranged at the upper part of the atomizer, and an air inlet is arranged at the lower part of the atomizer.

[0019] As an embodiment of the utility model, it also includes an external device, which is connected to the second connecting tube of the atomizing connector; the external device is used to reduce the pressure in the exposure chamber; and / or the external device is used to dilute the concentration of the original drug in the exposure chamber; and / or the external device is used to clean the exposure chamber.

[0020] Compared with the prior art, the beneficial effects of the utility model are:

[0021] By adding an atomization connector and providing multiple first connecting pipes to connect multiple atomizers, the concentration of the original drug in the exposure chamber can be well adjusted without concentrating the original drug, thereby improving the experimental efficiency and avoiding or reducing harm to the operator. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0023] Figure 1 It is an atomizing connector provided by the utility model;

[0024] Figure 2 This is a schematic diagram of connection between another atomizing connector and an atomizer provided by the utility model.

[0025] Description of reference numerals:

[0026] 100, atomizing connector; 110, connecting base; 120, first connecting pipe; 121, root; 122, tip; 124, collar; 130, second connecting pipe; 140, switch valve;

[0027] 200, atomizer; 210, air source inlet pipe; 220, drug inlet. DETAILED DESCRIPTION

[0028] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention. In addition, it should be understood that the specific implementation methods described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention. In the present invention, unless otherwise stated, the directional words used, such as "upper", "lower", "left", "right", "front", and "back", generally refer to the upper, lower, left, and right of the device in actual use or working state, specifically the drawing direction in the accompanying drawings.

[0029] It should be noted that the description order of the following embodiments is not intended to limit the preferred order of the embodiments of the present utility model. In addition, in the following embodiments, the description of each embodiment has its own emphasis. For parts not described in detail in one embodiment, please refer to the relevant description of other embodiments. Example

[0030] Please read first Figure 2 , the figure shows an atomizing connector 100, which is used to connect multiple atomizers 200 and an exposure chamber (not shown in the figure), and the exposure chamber is connected to a fixture (not shown in the figure) containing experimental animals (such as mice). The exposure chamber has a hollow opening structure on one side facing the connection base 110. The atomizing connector 100 is sealed and connected to the exposure chamber (not shown in the figure) to form an exposure cavity (not shown in the figure).

[0031] It can be understood that the nebulizer 200 is used to atomize the original drug, and there are multiple implementation schemes in the prior art, which will not be described in detail. Accordingly, the exposure chamber is used to distribute the atomized original drug to multiple holders, and there are multiple implementation schemes in the prior art, which will not be described in detail. Accordingly, for the structure of the holder, there are many implementation schemes in the prior art, such as the oral and nasal inhalation administration experimental animal holder disclosed in the utility model CN202420541150.2, which will not be described in detail.

[0032] Please continue reading Figure 2 The atomizing connector 100 includes a connecting base 110 and a plurality of first connecting tubes 120, and the plurality of first connecting tubes 120 do not interfere with each other. One side of the connecting base 110 is sealed and connected to the exposure chamber to form an exposure chamber, and the other side of the connecting base 110 is fixedly connected to the first connecting tube 120, so that the first connecting tube 120 can be connected to the exposure chamber through the connecting base 110. Figure 2 In this embodiment, the upper side of the connection base 110 is fixedly connected and communicated with the first connecting pipe 120, and the lower side is sealed and connected with the exposure cabin to form an exposure cavity.

[0033] The connection base 110 is provided with a plurality of first connecting tubes 120 of the same structure, that is, at least two first connecting tubes 120 are provided, preferably an even number of first connecting tubes 120 are provided, and the even number of first connecting tubes 120 are evenly distributed circumferentially on the connection base 110. The atomizer 200 is provided with a plurality of first connecting tubes 120, and the atomizer 200 is provided with a one-to-one correspondence with the first connecting tubes 120. The first connecting tube 120 includes a root 121 and a tip 122 that are fixedly connected. One side of the root 121 of the first connecting tube 120 is fixedly connected to the connection base 110, and the other side is fixedly connected to the tip 122. The tip 122 is used to be sealed, fixed and connected to the atomizer 200. The root 121 and the tip 122 are preferably manufactured in one piece.

[0034] In a preferred embodiment, the root 121 is preferably arranged along the axial direction of the connection base 110. Figure 2The tip 122 is preferably arranged in an inclined manner substantially along the radial direction of the connection base 110, and the end of the tip 122 connected to the atomizer 200 is arranged on the side away from the axis of the connection base 110 relative to the end of the tip 122 connected to the root 121. Figure 2 The tip 122 is extended along the axis away from the connecting base 110, and the end of the tip 122 away from the root 121 is higher than the end close to the root 121, so that the medicine atomized by the nebulizer 200 can stick to the inner walls of the tip 122 and the root 121 as little as possible when passing through the tip 122 and the root 121.

[0035] The atomizer 200 connector also includes an adjusting member, which is connected to the first connecting pipe 120 and is used to adjust the pipeline flow state of the first connecting pipe 120. In one embodiment, the adjusting member is a valve, and the valve is preferably a manual switch valve, which can well realize the opening or closing of the first connecting pipe 120; in another alternative embodiment, the valve is a solenoid valve, which can freely adjust the flow state of the flow channel of the first connecting pipe 120. There are many implementation schemes of the switch valve in the prior art, and the utility model will not be repeated here.

[0036] Of course, in addition to setting a switch valve on the first connecting tube 120, the first connecting tube 120 can also be selectively closed by setting the regulating member as a blocking member to block the first connecting tube. At this time, the blocking member is set at the end of the tip 122 away from the root 121 and is detachably sealed with the tip 122. Naturally, the tip 122 is also detachably connected to the atomizer 200 at this time, and the tip 122 selects the atomizer 200 or the blocking member for connection. It can be understood that the regulating member in the scheme of the utility model, as long as it can realize the selective adjustment of the flow state of multiple first connecting tubes 120, such as adjusting to open, close or open a specific ratio, the utility model does not limit the specific implementation plan, for example, it can be achieved by setting a switch valve, or by setting a blocking member, or other switch structures.

[0037] When it is necessary to conduct drug experiments on the original drug, the connection base 110 is sealed and fixed in the exposure chamber, and the atomizers 200 are respectively installed for the multiple first connecting tubes 120 in turn, and then the flow state of the multiple first connecting tubes 120 is adjusted by the adjustment member, such as closing the flow passage of part of the first connecting tubes 120; or adjusting the flow passage of at least part of the first connecting tubes 120, such as adjusting the flow passage from 100% to 50%. Then, the multiple atomizers 200 corresponding to the multiple first connecting tubes 120 are started, so that the original drug is atomized by the multiple atomizers 200 and enters the exposure chamber through the multiple first connecting tubes 120 for mixing.

[0038] It should be noted that for the original medicine atomized by multiple atomizers 200, multiple atomizers 200 can be original medicines of different components / concentrations, and then multiple original medicines of different components / concentrations are atomized and mixed in the exposure chamber. At this time, there is no need for operators to mix the original medicines, which can also meet the experimental needs, improve the experimental efficiency, and do not need to worry about waste, reducing costs. Of course, multiple atomizers 200 can also be original medicines of the same component / concentration, and at this time, there is no need for operators to concentrate the original medicines, which can also meet the experimental needs and can also improve the experimental efficiency.

[0039] In the prior art, since a single atomization chamber is only connected to one atomizer 200, and the concentration of the atomizer 200 is relatively fixed, even if it is set to the maximum aerosol generation efficiency, a single atomizer cannot meet the target aerosol dosage required for non-clinical efficacy, pharmacokinetic and safety evaluation studies. When it is necessary to adjust the concentration of the original drug in the exposure chamber, the original drug needs to be concentrated and mixed before use, which is relatively cumbersome for the operator, reduces the experimental efficiency, and some unapproved drugs may enter the air during the process and cause harm to the operator.

[0040] According to the solution of the utility model, by adding an atomizing connector 100 and providing a plurality of first connecting tubes 120 to connect a plurality of atomizers 200, the concentration of the original drug in the exposure chamber can be well regulated, and the regulation efficiency can be improved while avoiding or reducing the harm to the operator.

[0041] Please continue reading Figure 2 , the atomizing connector 100 is also provided with a collar 124, which is sleeved on one end of the tip 122 away from the root 121 and is sealed and movably connected with the tip 122, so that the collar 124 can move freely on the upper tip 122. The inner wall of the collar 124 is provided with a thread for threaded connection with the atomizer 200. In an alternative embodiment, the collar 124 is fixedly arranged on the tip 122 and is integrally connected and fixed with the tip 122, and the atomizer 200 is sealedly connected with the first connecting pipe 120 by threaded and sealed connection with the collar 124. In another replaceable embodiment, threads are provided on the ends of the atomizer 200 and the tip 122 away from the root 121, the inner wall of the ring 124 on the side close to the tip 122 is threadedly sealed to the tip 122, and the inner wall on the side close to the atomizer 200 is threadedly sealed to the atomizer 200, thereby realizing a detachable connection between the atomizer 200 and the tip 122.

[0042] Please continue reading Figure 2The upper part of the atomizer 200 is provided with a drug inlet 220 for communicating with the original drug chamber (not shown in the figure) containing the original drug, and the lower part of the atomizer 200 is provided with an air inlet for communicating with the air source air inlet pipe 210 to achieve communication with the external air source, thereby completing atomization. The advantage of such a setting is that the original drug can be more fully atomized in the atomizer 200, thereby improving the atomization efficiency.

[0043] Please continue reading Figure 2 The atomizer 200 is preferably a German PARI atomizer, which can better cooperate with the atomizer connector 100 provided by the utility model to adjust the concentration of the original drug in the exposure chamber. Example

[0044] The difference between this embodiment and embodiment 1 is that the atomizing connector 100 of this embodiment further includes a second connecting pipe 130, and a plurality of first connecting pipes are provided with a plurality of manual shutoff valves. A plurality of switch valves 140 correspond to the plurality of first connecting pipes 120, respectively, and the switch valves 140 are provided at the root 121 of the first connecting pipe 120, and the root 121 is provided to extend along the axial direction of the connecting base 110.

[0045] See also Figure 1 One side of the connecting base 110 is sealed and connected to the exposure chamber to form an exposure chamber, and the other side of the connecting base 110 is fixedly connected to a plurality of first connecting tubes 120 and a second connecting tube 130, respectively, so that the plurality of first connecting tubes 120 and the second connecting tube 130 can be connected to the exposure chamber through the connecting base 110. The plurality of first connecting tubes 120 do not interfere with each other, and the second connecting tubes do not interfere with the first connecting tubes 120. Preferably, the second connecting tube is arranged in the middle of the plurality of first connecting tubes. Figure 1 In this embodiment, the upper side of the connection base 110 is fixedly connected and communicated with the first connecting pipe 120 and the second connecting pipe 130 respectively, and the lower side is sealed and connected with the exposure cabin to form an exposure cavity.

[0046] The second connecting pipe 130 is used to communicate with an external device to achieve at least one of diluting the exposure chamber, adjusting the pressure of the exposure chamber (especially reducing the pressure of the exposure chamber) and cleaning the exposure chamber. There are many external devices in the prior art that can achieve at least one of the above functions, and the present invention does not limit this.

[0047] In one embodiment, the external device is an atomizer for atomizing pure water, and the concentration of the original drug is diluted by increasing the water content in the exposure chamber; or the external device is a gas delivery device capable of inputting clean air into the exposure chamber, such as an air pump, and the concentration of the original drug in the exposure chamber is diluted by increasing the air flow in the entire atomization connector 100-exposure chamber-fixator containing the experimental animal; or the concentration of the original drug in the exposure chamber is diluted by injecting a substance that can neutralize or absorb the original drug, such as an adsorption device (such as activated carbon particles, carbon fiber, etc.).

[0048] In another embodiment, the external device is a pressure relief valve, or a pressure relief device capable of relieving pressure, such as an air pump, to achieve pressure regulation in the exposure chamber.

[0049] In another embodiment, the external device is a water pump, or a cleaning device capable of cleaning the exposure cavity, such as a steam engine, to achieve cleaning of the exposure cavity.

[0050] Thus, through this embodiment, the efficiency of the operator can be further improved. It can be understood that in the prior art, since only one atomizer 200 is used, the problem of too low concentration of the original drug is faced, and the problem when the concentration of the original drug is too high is not considered. In Example 1, since the atomized original drug cannot be completely absorbed by the experimental animal, as the experiment increases, the concentration of the original drug in the entire exposure chamber continues to increase, especially when multiple atomizers 200 are used simultaneously through multiple first connecting tubes 120, the concentration and pressure of the retained original drug in the exposure chamber are high, and cannot be relieved in a short time. Through the solution of the utility model, by adding a second connecting hole, it is ensured that at least the concentration of the original drug in the exposure chamber can be diluted, or the pressure of the exposure chamber can be adjusted.

[0051] In order to more clearly illustrate the effect of the embodiment 1 of the present scheme and the prior art, an experimental example is now described, and the experimental steps are as follows:

[0052] ① Determination and selection of animal species: small animal experimental models are constructed with mice and rats, and large animal experimental models are constructed with dogs or monkeys. The experimental animals are half male and half female, and are provided with 12 hours of sunlight per day. The ambient temperature is monitored and controlled within the range of 18-26°C and the relative humidity is within the range of 40-70%;

[0053] ② Preparation of test products: Weigh the liquid original drug to be evaluated and dilute it to an appropriate concentration with buffer as the experimental group; buffer as control group 1; 0.9% sodium chloride injection as control group 2;

[0054] ③ Oral and nasal exposure inhalation administration method: multiple nebulizers are connected in parallel to the oral and nasal inhalation exposure system, and the test sample is atomized after setting the designed administration rate (such as the target aerosol generation of 20 L / min, 2 nebulizers can be selected and set to 10L / min; 4 nebulizers can also be selected and set to 5L / min). The aerosol generated by each nebulizer enters the exposure chamber and is fully mixed, and then connected to each experimental animal. The experimental animal is fixed on the fixture for oral and nasal exposure administration.

[0055] ④ Oral and nasal exposure quality control: After the oral and nasal exposure system is stable, the aerosol concentration, particle size distribution, temperature, relative humidity, oxygen concentration, carbon dioxide concentration and other indicators are measured and analyzed after sampling. The detection method is as follows:

[0056]

[0057] After testing, the atomization connector and oral and nasal inhalation exposure system provided by the utility model meet the requirements in terms of mixing efficiency and original drug concentration.

[0058] The above is a detailed introduction to the scheme of the utility model. Specific examples are used in this article to illustrate the principle and implementation method of the utility model. The description of the above embodiments is only used to help understand the method and core idea of ​​the utility model. At the same time, for general technicians in this field, according to the idea of ​​the utility model, there will be changes in the specific implementation method and application scope. In summary, the content of this specification should not be understood as a limitation on the utility model.

[0059] References throughout the specification to "one embodiment," "an embodiment," or "a specific embodiment" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment of the present invention, and not necessarily in all embodiments. Thus, various appearances of the phrases "in one embodiment," "in an embodiment," or "in a specific embodiment" in different places throughout the specification do not necessarily refer to the same embodiment. In addition, the particular features, structures, or characteristics of any specific embodiment of the present invention may be combined with one or more other embodiments in any suitable manner. It should be understood that other variations and modifications of the embodiments of the present invention described and illustrated herein may be based on the teachings herein and will be considered part of the spirit and scope of the present invention.

[0060] It should also be understood that one or more of the elements shown in the figures may also be implemented in a more separate or more integrated manner, or even removed because they are inoperable in certain circumstances or provided because they may be useful depending on the application.

[0061] In addition, unless otherwise explicitly indicated, any marking arrows in the drawings should be regarded as exemplary only and not limiting. In addition, unless otherwise indicated, the term "or" used herein is generally intended to mean "and / or". In the case where the term is not clear because it is anticipated that the ability to separate or combine is provided, the combination of components or steps will also be regarded as indicated.

Claims

1. An atomization connector, connecting an atomizer for atomizing the original drug and an exposure chamber connected to a fixture for accommodating experimental animals, characterized in that: It includes a connecting base, a first connecting pipe, a second connecting pipe and an adjusting member, One side of the connecting base is sealed with the exposure cabin to form an exposure cavity, and the other side is fixedly connected with the second connecting pipe and the plurality of the first connecting pipes; The first connecting pipe is fixedly connected to the atomizer; The plurality of adjusting members are respectively and correspondingly arranged on the plurality of the first communicating pipes, and are used for selectively adjusting the pipeline flow state of the first communicating pipes; The second connecting pipe does not interfere with the first connecting pipe, and the second connecting pipe is connected to an external device, wherein The second connecting pipe is used to reduce the pressure in the exposure chamber through the external device, and / or to dilute the concentration of the original drug in the exposure chamber through the external device.

2. The atomizing connector according to claim 1, characterized in that: The first connecting pipe comprises a root portion and a tip portion which are fixedly connected, wherein one end of the root portion away from the tip portion is fixedly connected to the connecting base, and one end of the tip portion away from the root portion is fixedly connected to the atomizer, wherein The root is arranged along the axial direction of the connecting base; The tip is tilted along the radial direction of the connection base, and one end of the tip connected to the atomizer is arranged on a side away from the axis of the connection base relative to one end of the tip connected to the root.

3. The atomizing connector according to claim 2, characterized in that: The plurality of first communicating tubes are evenly arranged in the circumferential direction of the connecting base, and the second communicating tube is arranged between the plurality of first communicating tubes.

4. The atomizing connector according to claim 2, characterized in that: The regulating member is a valve connected to the first connecting pipe; or The regulating member is a plugging member that is detachably sealed with the tip, the plugging member matches with an end of the tip away from the root, and the tip is detachably fixedly connected with the atomizer.

5. The atomizing connector according to claim 4, characterized in that: The valve connection is arranged at the root of the first connecting pipe and close to one side of the connecting base; The valve is a solenoid valve or a manual shut-off valve.

6. The atomizing connector according to any one of claims 1 to 5, characterized in that: The second connecting pipe is also used for cleaning the exposure cavity through the external equipment.

7. The atomizer connector according to any one of claims 1 to 5, characterized in that: Also includes a collar, The plurality of collars are respectively fixed on one end of the plurality of first connecting tubes close to the atomizer, or the plurality of collars are respectively movably sleeved on one end of the plurality of first connecting tubes close to the atomizer and are sealed and connected to the first connecting tubes; The plurality of collars are respectively connected to the plurality of atomizers in a detachable sealing manner.

8. An oral and nasal inhalation exposure system, characterized in that: It comprises a nebulizer for nebulizing the original drug, a fixture for accommodating experimental animals, an exposure chamber and a nebulizer connector as claimed in any one of claims 1 to 7, wherein The atomizing connector is used to connect the exposure cabin and the plurality of atomizers, and the atomizing connector is sealed with the exposure cabin to form an exposure cavity; The exposure chamber is communicated with the plurality of the holders, and the exposure chamber is used to mix the original drugs in the plurality of the atomizers and then deliver them to the plurality of the holders.

9. The oral and nasal inhalation exposure system according to claim 8, characterized in that: The upper part of the atomizer is provided with a drug adding port for adding the original drug, and the lower part of the atomizer is provided with an air inlet.

10. The oral and nasal inhalation exposure system according to claim 8 or 9, characterized in that: Also included is an external device, the external device being in communication with the second communication pipe of the atomizing connection piece; The external device is used to reduce the pressure in the exposure chamber; and / or The external device is used to dilute the concentration of the original drug in the exposure chamber; and / or The external device is used to clean the exposure chamber.

Images